Syeda Mahrukh Hussnain Naqvi

Rachid Baz 1 collaboration

Jae-Hoon Lee 1 collaboration

Jason Brayer 1 collaboration

Nancy Hillgruber 1 collaboration

Brooke L Fridley 1 collaboration

Kenneth H Shain 1 collaboration

Daniel M Sullivan 1 collaboration

Melissa Alsina 1 collaboration

Kristy Kummerow Broman 1 collaboration

Tasha Hughes 1 collaboration

Lesly Dossett 1 collaboration

James Sun 1 collaboration

Dennis Kirichenko 1 collaboration

Michael J Carr 1 collaboration

Avinash Sharma 1 collaboration

Edmund K Bartlett 1 collaboration

Amanda A G Nijhuis 1 collaboration

John F Thompson 1 collaboration

Tina J Hieken 1 collaboration

Lisa Kottschade 1 collaboration

Jennifer Downs 1 collaboration

David E Gyorki 1 collaboration

Emma Stahlie 1 collaboration

Alexander van Akkooi 1 collaboration

David W Ollila 1 collaboration

Jill Frank 1 collaboration

Yun Song 1 collaboration

Giorgos Karakousis 1 collaboration

Marc Moncrieff 1 collaboration

Jenny Nobes 1 collaboration

John Vetto 1 collaboration

Dale Han 1 collaboration

Jeffrey M Farma 1 collaboration

Jeremiah L Deneve 1 collaboration

Martin D Fleming 1 collaboration

Matthew C Perez 1 collaboration

Michael C Lowe 1 collaboration

Roger Olofsson Bagge 1 collaboration

Jan Mattsson 1 collaboration

Ann Y Lee 1 collaboration

Russell S Berman 1 collaboration

Harvey Chai 1 collaboration

Hidde M Kroon 1 collaboration

Juri Teras 1 collaboration

Roland M Teras 1 collaboration

Norma E Farrow 1 collaboration

Georgia Beasley 1 collaboration

Jane Yuet Ching Hui 1 collaboration

Lukas Been 1 collaboration

Schelto Kruijff 1 collaboration

Youngchul Kim 1 collaboration

Amod A Sarnaik 1 collaboration

Vernon K Sondak 1 collaboration

Jonathan S Zager 1 collaboration

Syeda Mahrukh Hussnain Naqvi

Affiliations

Publications (2)

Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.

Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).

Réseau de co-auteurs